NeoStem, Inc. (AMEX: NBS; Stock Twits: $NBS) is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development.
Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and has commenced enrollment in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson. NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.
Neostem announced that the Company has been invited to present at two upcoming conferences in March, at which the Company will provide corporate updates.
Cowen and Company's 32nd Annual Health Care Conference
Date: March 5, 2012, 2:50 PM
Venue: Marriott Copley Place, Boston, MA
About: "Cowen and Company conferences are major industry events attracting top institutional investors as well as leading companies in Technology, Health Care, Consumer & Retail, Aerospace & Defense, and Alternative Energy. The company hosts several industry-specific conferences each year and have put together an exciting schedule of upcoming conferences. Combining company presentations, on-stage interviews, panel discussions and management breakout sessions, these conferences give institutional investors direct contact with senior management and industry experts, and provide an introduction to dynamic emerging companies." Read more at Cowen.com.
Maxim Group's 5th Annual Growth Conference
Date: March 26, 2012, 9:00 AM
Venue: Grand Hyatt, New York, NY
About: "The 5th annual Maxim Group Growth Conference is a senior level, interactive conference experience designed to meet the needs of our institutional clients. We combine company presentations, break-out sessions and management 1-on-1 meetings to assist clients with gaining an in-depth perspective on the issues affecting the growth of our presenting companies. The conference will also feature a series of panel discussions, a networking lunch and post conference cocktail reception. This one-day event will feature more than 80 presentations across six designated tracks from a diverse selection of both domestic and international companies." Read more at MaximGRP.com.